GlaxoSmithKline Diabetes Drug Faces U.S. Approval Delay

Published: Aug 02, 2013

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

U.S. regulators have pushed back an approval decision on GlaxoSmithKline's experimental diabetes drug albiglutide by three months until April 15, 2014, Britain's biggest drugmaker said on Friday. A separate filing for the drug in Europe is progressing on schedule. The once-weekly treatment for type 2 diabetes belongs to the same class of injectable GLP-1 drugs as Victoza, from Novo Nordisk, and Byetta and Bydureon, from Bristol-Myers Squibb and AstraZeneca.

Help employers find you! Check out all the jobs and post your resume.

Back to news